This bill introduces new safety and procedural requirements for clinician-administered drugs by amending the Managed Care Law (RSA 420-J). It defines a "clinician-administered drug" as an outpatient prescription drug that cannot be reasonably self-administered and is typically administered by a healthcare professional in a clinical setting. The bill prohibits health insurers and pharmacy benefit managers (PBMs) from mandating that these drugs be dispensed through specific pharmacies (referred to as "white bagging") or transported by patients to providers (known as "brown bagging") without prior written consent from both the provider and the patient, as well as a written agreement outlining responsibilities between the provider and the pharmacy.

Additionally, the bill ensures that health insurers and PBMs cannot interfere with a patient's right to choose their provider or pharmacy for clinician-administered drugs, nor can they impose additional fees or restrict coverage based on the pharmacy used. The effective date for these provisions is set for January 1, 2027. The bill does not allocate funding or authorize new positions, and while it may lead to increased insurance premiums due to the prohibition of brown-bagging, the exact fiscal impact remains indeterminable.